Henan Newland Pharmaceutical Co. Ltd. A (SHE:301277) — Stock Price
Henan Newland Pharmaceutical Co. Ltd. A (SHE:301277) is currently trading at CN¥10.75 CNY, down 0.37% today. Over the past 52 weeks, shares have ranged between CN¥8.70 and CN¥15.06. This page tracks Henan Newland Pharmaceutical Co. Ltd. A's live share price on the SHE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 301277 market cap.
Henan Newland Pharmaceutical Co. Ltd. A (301277) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Henan Newland Pharmaceutical Co. Ltd. A's daily closing share price and trading volume on the SHE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Henan Newland Pharmaceutical Co. Ltd. A Income Statement — Revenue, Profit & Earnings by Year
Henan Newland Pharmaceutical Co. Ltd. A's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | CN¥672.38 Million | CN¥726.44 Million | CN¥651.44 Million | CN¥627.36 Million | CN¥513.84 Million |
| Cost of Revenue | CN¥437.63 Million | CN¥431.86 Million | CN¥391.92 Million | CN¥404.01 Million | CN¥307.82 Million |
| Gross Profit | CN¥234.74 Million | CN¥294.58 Million | CN¥259.51 Million | CN¥223.36 Million | CN¥206.02 Million |
| Research & Development | CN¥46.18 Million | CN¥55.49 Million | CN¥51.96 Million | CN¥30.00 Million | CN¥20.59 Million |
| SG&A | CN¥21.65 Million | CN¥21.27 Million | CN¥17.34 Million | CN¥11.85 Million | CN¥13.52 Million |
| Total Operating Expenses | CN¥539.02 Million | CN¥535.08 Million | CN¥490.91 Million | CN¥478.09 Million | CN¥363.51 Million |
| Operating Income | CN¥133.36 Million | CN¥191.36 Million | CN¥160.53 Million | CN¥149.27 Million | CN¥150.33 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | CN¥211.97K | CN¥89.32K | CN¥132.85K | CN¥6.88 Million | CN¥6.71 Million |
| Income Before Tax | CN¥134.12 Million | CN¥197.35 Million | CN¥181.16 Million | CN¥142.88 Million | CN¥131.94 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | CN¥121.25 Million | CN¥173.63 Million | CN¥158.98 Million | CN¥132.30 Million | CN¥114.98 Million |
Henan Newland Pharmaceutical Co. Ltd. A Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Henan Newland Pharmaceutical Co. Ltd. A's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | CN¥1.78 Billion | CN¥1.81 Billion | CN¥1.61 Billion | CN¥1.53 Billion | CN¥667.90 Million |
| Total Current Assets | CN¥1.07 Billion | CN¥1.20 Billion | CN¥1.16 Billion | CN¥1.19 Billion | CN¥401.00 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | CN¥549.55 Million | CN¥525.16 Million | CN¥589.50 Million | CN¥701.36 Million | CN¥8.67 Million |
| Net Receivables | CN¥130.97 Million | CN¥149.60 Million | CN¥109.00 Million | CN¥179.15 Million | CN¥151.12 Million |
| Inventory | CN¥72.37 Million | CN¥45.06 Million | CN¥31.00 Million | CN¥53.52 Million | CN¥78.57 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | CN¥228.49 Million | CN¥270.69 Million | CN¥160.02 Million | CN¥174.58 Million | CN¥261.53 Million |
| Total Current Liabilities | CN¥170.35 Million | CN¥216.78 Million | CN¥139.47 Million | CN¥156.01 Million | CN¥220.58 Million |
| Long-term Debt | — | — | — | CN¥0.00 | CN¥30.39 Million |
| Net Debt | — | — | — | — | CN¥87.51 Million |
| Total Stockholder Equity | CN¥1.55 Billion | CN¥1.54 Billion | CN¥1.45 Billion | CN¥1.36 Billion | CN¥402.53 Million |
| Retained Earnings | CN¥507.92 Million | CN¥511.47 Million | CN¥436.25 Million | CN¥361.20 Million | CN¥242.48 Million |
Henan Newland Pharmaceutical Co. Ltd. A Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Henan Newland Pharmaceutical Co. Ltd. A generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | CN¥116.94 Million | CN¥126.76 Million | CN¥259.46 Million | CN¥82.85 Million | CN¥49.08 Million |
| Capital Expenditures | CN¥101.38 Million | CN¥110.79 Million | CN¥96.51 Million | CN¥74.34 Million | CN¥25.40 Million |
| Free Cash Flow | CN¥15.55 Million | CN¥15.97 Million | CN¥162.94 Million | CN¥8.50 Million | CN¥23.68 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | CN¥112.02 Million | CN¥80.02 Million | CN¥66.68 Million | CN¥6.77 Million | CN¥36.70 Million |
| Stock-Based Compensation | — | — | — | — | CN¥3.71 Million |
| Depreciation | CN¥55.49 Million | CN¥37.84 Million | CN¥31.08 Million | CN¥24.24 Million | CN¥20.86 Million |
| Change in Cash | CN¥-112.16 Million | CN¥11.14 Million | CN¥223.51 Million | CN¥16.12 Million | CN¥-5.94 Million |
Henan Newland Pharmaceutical Co. Ltd. A Earnings History — EPS Actual vs. Analyst Estimates
Track Henan Newland Pharmaceutical Co. Ltd. A's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 31, 2026 | 0.09 | — | — |
| Dec 31, 2025 | 0.07 | — | — |
| Sep 30, 2025 | 0.04 | — | — |
| Jun 30, 2025 | 0.05 | — | — |
| Mar 31, 2025 | 0.14 | — | — |
| Dec 31, 2024 | 0.08 | — | — |
| Sep 30, 2024 | 0.08 | — | — |
| Jun 30, 2024 | 0.14 | — | — |